HRP20210244T1 - Moduliranje eksprimiranja virusa hepatitisa b (hbv) - Google Patents
Moduliranje eksprimiranja virusa hepatitisa b (hbv) Download PDFInfo
- Publication number
- HRP20210244T1 HRP20210244T1 HRP20210244TT HRP20210244T HRP20210244T1 HR P20210244 T1 HRP20210244 T1 HR P20210244T1 HR P20210244T T HRP20210244T T HR P20210244TT HR P20210244 T HRP20210244 T HR P20210244T HR P20210244 T1 HRP20210244 T1 HR P20210244T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- liver
- segment
- disease
- modified oligonucleotide
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000002777 nucleoside Substances 0.000 claims 8
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 125000003835 nucleoside group Chemical group 0.000 claims 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010023126 Jaundice Diseases 0.000 claims 2
- 206010058874 Viraemia Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 208000018191 liver inflammation Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (6)
1. Spoj, naznačen time što sadrži jednolančani modificirani oligonukleotid, namijenjen upotrebi u liječenju bolesti, poremećaja ili stanja povezanog s HBV kod subjekta, gdje je bolest, poremećaj ili stanje žutica, upala jetre, fibroza jetre, upala, ciroza jetre, zatajenje jetre, rak jetre, difuzna hepatocelularna upalna bolest, hemofagocitni sindrom, serumski hepatitis, viremija HBV, ili presađivanje povezano s bolešću jetre, gdje se jednolančani modificirani oligonukleotid sastoji od 20 spojenih nukleozida koji imaju slijed nukleobaza sa SEQ ID NO: 226 i sadrži:
razmačni segment, koji se sastoji od deset spojenih dezoksinukleozida;
5′ bočni segment, koji se sastoji od 5 spojenih nukleozida; i
3′ bočni segment, koji se sastoji od 5 spojenih nukleozida;
gdje je razmačni segment smješten između 5′ bočnog segmenta i 3′ bočnog segmenta, gdje svaki nukleozid svakog bočnog segmenta sadrži 2′-O-metoksietilirani šećer, gdje je svaka internukleozidna veza fosforotioatna veza, te gdje je svaki citozin 5-metilcitozin.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se spoj sastoji od jednolančanog modificiranog oligonukleotida.
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je spoj konjugirani protusmisleni spoj.
4. Pripravak namijenjen upotrebi u liječenju bolesti, poremećaja ili stanja povezanog s HBV kod subjekta, naznačen time što je bolest, poremećaj ili stanje žutica, upala jetre, fibroza jetre, upala, ciroza jetre, zatajenje jetre, rak jetre, difuzna hepatocelularna upalna bolest, hemofagocitni sindrom, serumski hepatitis, viremija HBV, ili presađivanje povezano s bolešću jetre,
gdje pripravak sadrži spoj, ili njegovu sol, i farmaceutski prihvatljivi nosač ili razrjeđivač,
gdje spoj sadrži jednolančani modificirani oligonukleotid,
gdje se jednolančani modificirani oligonukleotid sastoji od 20 spojenih nukleozida koji imaju slijed nukleobaza sa SEQ ID NO: 226 i sadrži:
razmačni segment, koji se sastoji od deset spojenih dezoksinukleozida;
5′ bočni segment, koji se sastoji od 5 spojenih nukleozida; i
3′ bočni segment, koji se sastoji od 5 spojenih nukleozida;
gdje je razmačni segment smješten između 5′ bočnog segmenta i 3′ bočnog segmenta, gdje svaki nukleozid svakog bočnog segmenta sadrži 2′-O-metoksietilirani šećer, gdje je svaka internukleozidna veza fosforotioatna veza, te gdje je svaki citozin 5-metilcitozin.
5. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što se spoj sastoji od jednolančanog modificiranog oligonukleotida.
6. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je spoj konjugirani protusmisleni spoj.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478040P | 2011-04-21 | 2011-04-21 | |
US201161478038P | 2011-04-21 | 2011-04-21 | |
US201261596692P | 2012-02-08 | 2012-02-08 | |
US201261596690P | 2012-02-08 | 2012-02-08 | |
EP19155538.2A EP3505528B1 (en) | 2011-04-21 | 2012-04-20 | Modulation of hepatitis b virus (hbv) expression |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210244T1 true HRP20210244T1 (hr) | 2021-04-30 |
Family
ID=47041953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210244TT HRP20210244T1 (hr) | 2011-04-21 | 2021-02-11 | Moduliranje eksprimiranja virusa hepatitisa b (hbv) |
Country Status (34)
Country | Link |
---|---|
US (7) | US8642752B2 (hr) |
EP (4) | EP3505528B1 (hr) |
JP (3) | JP6042871B2 (hr) |
KR (3) | KR102247463B1 (hr) |
CN (3) | CN111172162A (hr) |
AU (1) | AU2012245243B2 (hr) |
CA (1) | CA2833766C (hr) |
CL (1) | CL2013003053A1 (hr) |
CO (1) | CO6862103A2 (hr) |
CR (2) | CR20190207A (hr) |
CY (1) | CY1124327T1 (hr) |
DK (1) | DK3505528T3 (hr) |
DO (1) | DOP2013000246A (hr) |
EA (1) | EA029137B1 (hr) |
ES (1) | ES2856266T3 (hr) |
HR (1) | HRP20210244T1 (hr) |
HU (1) | HUE053401T2 (hr) |
IL (2) | IL228874B (hr) |
LT (1) | LT3505528T (hr) |
MX (2) | MX347253B (hr) |
MY (1) | MY169474A (hr) |
NZ (2) | NZ705820A (hr) |
PE (2) | PE20181267A1 (hr) |
PH (1) | PH12013502157A1 (hr) |
PL (1) | PL3505528T3 (hr) |
PT (1) | PT3505528T (hr) |
RS (1) | RS61447B1 (hr) |
RU (1) | RU2667524C2 (hr) |
SG (2) | SG194555A1 (hr) |
SI (1) | SI3505528T1 (hr) |
TW (1) | TWI548745B (hr) |
UA (1) | UA118951C2 (hr) |
WO (1) | WO2012145697A1 (hr) |
ZA (1) | ZA201307620B (hr) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
DK2092065T4 (da) | 2006-10-18 | 2019-10-21 | Ionis Pharmaceuticals Inc | Antisense-forbindelser |
ES2626000T3 (es) | 2009-11-02 | 2017-07-21 | University Of Washington | Composiciones terapéuticas de nucleasas y métodos |
EP2606134B1 (en) * | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
IL300276B1 (en) | 2011-04-29 | 2024-07-01 | Univ Washington | Therapeutic nuclease preparations and methods |
US8809293B2 (en) | 2011-06-30 | 2014-08-19 | Arrowhead Madison Inc. | Compositions and methods for inhibiting gene expression of hepatitis B virus |
WO2013022966A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
WO2014011900A2 (en) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibitors of the fibroblast growth factor receptor |
JP6270846B2 (ja) | 2012-08-30 | 2018-01-31 | レプリコール インコーポレーティッド | B型肝炎感染及びd型肝炎感染の治療方法 |
US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
EP2906258A4 (en) | 2012-10-15 | 2016-08-10 | Ionis Pharmaceuticals Inc | COMPOSITIONS FOR MODULATING THE EXPRESSION OF C90RF72 |
EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHODS OF MONITORING C9ORF72 EXPRESSION |
EP2906696B2 (en) | 2012-10-15 | 2022-12-14 | Ionis Pharmaceuticals, Inc. | Methods for modulating c9orf72 expression |
EP2920304B1 (en) | 2012-11-15 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
EP2951305B1 (en) | 2013-01-30 | 2018-08-15 | F.Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
EP2992098B1 (en) | 2013-05-01 | 2019-03-27 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating hbv and ttr expression |
US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
WO2015054676A2 (en) | 2013-10-11 | 2015-04-16 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
WO2015066557A1 (en) | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease molecules with altered glycosylation and methods |
WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
JP6622214B2 (ja) | 2014-04-01 | 2019-12-18 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Sod−1発現を調節するための組成物 |
BR122020024443B1 (pt) | 2014-05-01 | 2022-02-22 | Ionis Pharmaceuticals, Inc | Composto e composição farmacêutica para modulação da expressão de angptl3 |
KR102369736B1 (ko) | 2014-05-01 | 2022-03-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 보체 인자 b 발현을 조절하기 위한 조성물 및 방법 |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
EA202191771A1 (ru) * | 2015-03-24 | 2022-01-31 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
SG11201708468YA (en) * | 2015-04-16 | 2017-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
US20170016000A1 (en) | 2015-07-17 | 2017-01-19 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
BR122023026882A2 (pt) | 2015-11-06 | 2024-01-23 | Ionis Pharmaceuticals, Inc | Uso de um composto oligomérico |
EP3426261A4 (en) | 2016-03-07 | 2020-03-25 | Arrowhead Pharmaceuticals, Inc. | TARGETED LIGANDS FOR THERAPEUTIC CONNECTIONS |
RS61528B1 (sr) | 2016-03-14 | 2021-04-29 | Hoffmann La Roche | Oligonukleotidi za smanjenje ekspresije pd-l1 |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
CN109790526A (zh) | 2016-07-01 | 2019-05-21 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
AU2017320582B2 (en) | 2016-09-02 | 2023-11-16 | Arrowhead Pharmaceuticals, Inc | Targeting ligands |
CA3037042A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Biopharma, Inc. | Modified oligonucleotides and methods of use |
WO2018067900A1 (en) | 2016-10-06 | 2018-04-12 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
JP2019533472A (ja) * | 2016-11-11 | 2019-11-21 | ヤンセン バイオファーマ インク. | Hbv cccdnaのオリゴヌクレオチド標的化戦略 |
JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
CA3047076A1 (en) * | 2016-12-13 | 2018-06-21 | Am Sciences Inc | Pharmaceutical composition for preventing or treating hepatitis b |
WO2018112124A1 (en) | 2016-12-15 | 2018-06-21 | Meharry Medical College | Antiviral agents |
CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
CN106701763B (zh) * | 2016-12-30 | 2019-07-19 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9靶向敲除人乙肝病毒P基因及其特异性gRNA |
CN106916905B (zh) * | 2017-01-17 | 2018-06-08 | 重庆医科大学附属儿童医院 | 隐匿性乙肝病毒检测试剂盒及其检测方法 |
SG11201909572QA (en) | 2017-04-18 | 2019-11-28 | Alnylam Pharmaceuticals Inc | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11555191B2 (en) | 2017-09-01 | 2023-01-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitor for use for preventing and/or treating an infection with hepatitis B virus |
UA126931C2 (uk) | 2017-10-16 | 2023-02-22 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B |
IL282881B1 (en) | 2017-10-20 | 2024-06-01 | Dicerna Pharmaceuticals Inc | Methods for treating hepatitis B infection |
AU2019218987A1 (en) | 2018-02-12 | 2020-07-23 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
CA3097544A1 (en) | 2018-04-05 | 2019-10-10 | F. Hoffmann-La Roche Ag | Use of fubp1 inhibitors for treating hepatitis b virus infection |
MX2020013366A (es) | 2018-07-03 | 2021-03-09 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau. |
BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
MX2021001056A (es) | 2018-08-13 | 2021-04-12 | Alnylam Pharmaceuticals Inc | Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas. |
CN109234275A (zh) * | 2018-08-30 | 2019-01-18 | 山东省立医院 | 一种可以同时抑制乙肝病毒dna和乙肝表面抗原的反义核苷酸 |
JP2022524007A (ja) * | 2019-03-05 | 2022-04-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | B型肝炎免疫化レジメンおよび組成物 |
US11466274B2 (en) | 2019-05-31 | 2022-10-11 | Aligos Therapeutics, Inc. | Modified gapmer oligonucleotides and methods of use |
WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | B型肝炎治療用核酸分子 |
CN114901821A (zh) | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
WO2021122993A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of saraf inhibitors for treating hepatitis b virus infection |
CN114829599A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途 |
WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
JP2023506550A (ja) | 2019-12-19 | 2023-02-16 | エフ. ホフマン-ラ ロシュ エージー. | B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用 |
WO2021226019A2 (en) * | 2020-05-04 | 2021-11-11 | The Regents Of The University Of California | Compositions and methods for treating viral infections |
US20220056451A1 (en) * | 2020-07-27 | 2022-02-24 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 rtel1 表現之增強型寡核苷酸 |
AU2022395876A1 (en) * | 2021-11-29 | 2024-05-09 | Shanghai Argo Biopharmaceutical Co., Ltd. | Composition and method for inhibiting expression of hepatitis b virus (hbv) protein |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
KR20240131441A (ko) * | 2022-01-10 | 2024-08-30 | 오스퍼바이오 테라퓨틱스 인크. | B형 간염 바이러스(hbv) 발현의 조절 |
CN118660704A (zh) | 2022-01-28 | 2024-09-17 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗乙型肝炎病毒感染的组合疗法 |
WO2023187612A1 (en) | 2022-03-29 | 2023-10-05 | Glaxosmithkline Intellectual Property Development Limited | Method of treating chronic hepatitis b |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5780219A (en) | 1989-07-11 | 1998-07-14 | Gen-Probe Incorporated | Nucleic acid amplification oligonucleotides and probes to human hepatitis B virus |
GB9006924D0 (en) | 1990-03-28 | 1990-05-23 | Imperial College | Prognosis of hepatitis infection |
JPH05506993A (ja) | 1990-04-20 | 1993-10-14 | ザ・ジェネラル・ホスピタル・コーポレーション | ウイルスの複製を防止する方法 |
US5610050A (en) | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
AU8412991A (en) * | 1990-07-27 | 1992-03-02 | Chiron Corporation | Large comb-type branched polynucleotides |
US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
EP0618924B1 (en) | 1991-12-23 | 2001-02-14 | Bayer Corporation | Hbv amplifier probes for use in solution phase sandwich hybridization assays |
US6017756A (en) | 1992-05-14 | 2000-01-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting hepatitis B virus replication |
US20030068301A1 (en) * | 1992-05-14 | 2003-04-10 | Kenneth Draper | Method and reagent for inhibiting hepatitis B virus replication |
US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
US5736334A (en) | 1993-04-12 | 1998-04-07 | Abbott Laboratories | Nucleotide sequences and process for amplifying and detection of hepatitis B viral DNA |
CA2167056A1 (en) | 1993-07-13 | 1995-01-26 | Uwe Spies | Nucleotide sequences and process for amplifying and detection of hepatitis b virus |
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
JPH09507062A (ja) * | 1993-12-23 | 1997-07-15 | アポロン インク. | 抗b型肝炎ウイルスオリゴヌクレオチド |
US5728518A (en) | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US5856459A (en) | 1995-06-06 | 1999-01-05 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
US6217858B1 (en) | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
ZA973367B (en) | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
CN1057302C (zh) * | 1997-08-27 | 2000-10-11 | 中国科学院上海生物化学研究所 | 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸 |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
EP1557424A1 (en) | 1997-09-12 | 2005-07-27 | Exiqon A/S | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
CN1081069C (zh) * | 1998-08-14 | 2002-03-20 | 饶纬华 | 乙型肝炎治疗性疫苗及其制备方法 |
ES2283298T3 (es) | 1999-05-04 | 2007-11-01 | Santaris Pharma A/S | Analogos de l-ribo-lna. |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
US20040002153A1 (en) * | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
WO2001016312A2 (en) | 1999-08-31 | 2001-03-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based modulators of gene expression |
EP1238061A2 (en) | 1999-11-24 | 2002-09-11 | Pharmasset, Ltd. | A new genotype of hepatitis b virus |
CA2392853A1 (en) | 1999-12-03 | 2001-06-07 | Innogenetics N.V. | Hbv sequences |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
EP1152063A1 (en) | 2000-05-03 | 2001-11-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Method of diagnosing HBV infection stages |
AU2001269092A1 (en) | 2000-06-27 | 2002-01-08 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
EP1383782A1 (en) | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
US20080161256A1 (en) | 2001-05-18 | 2008-07-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
JP2005505289A (ja) | 2001-10-09 | 2005-02-24 | カイロン コーポレイション | B型肝炎ウイルスdnaの捕獲、検出および定量のためのオリゴヌクレオチドの同定 |
US6828105B2 (en) | 2001-10-16 | 2004-12-07 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
US20050266422A1 (en) | 2002-02-20 | 2005-12-01 | Sirna Therapeutics, Inc. | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides |
EP2033967A1 (en) | 2002-04-12 | 2009-03-11 | Melbourne Health | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
US7015317B2 (en) | 2002-05-02 | 2006-03-21 | Abbott Laboratories | Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids |
ES2370169T3 (es) | 2002-06-14 | 2011-12-13 | Gen-Probe Incorporated | Composiciones y métodos para detectar el virus de la hepatitis b. |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
KR100855907B1 (ko) | 2002-09-13 | 2008-09-02 | 노파르티스 아게 | 내성 HBV 균주 치료용 β-L-2'-데옥시뉴클레오시드 및병용 요법 |
AU2003287502B2 (en) | 2002-11-05 | 2010-12-09 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
WO2004076629A2 (en) | 2003-02-27 | 2004-09-10 | Nucleonics Inc. | METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES |
CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
US20040191776A1 (en) | 2003-03-21 | 2004-09-30 | Pei-Jer Chen | Method for genotyping and quantifying Hepatitis B Virus |
US20040185452A1 (en) | 2003-03-21 | 2004-09-23 | Pei-Jer Chen | Identification of single nucleotide polymorphisms |
US7067249B2 (en) | 2003-05-19 | 2006-06-27 | The University Of Hong Kong | Inhibition of hepatitis B virus (HBV) replication by RNA interference |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
CN1836042A (zh) | 2003-06-12 | 2006-09-20 | 原子核物理公司 | 用于基因沉默的hbv和hcv保守序列 |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
EP1493822A1 (de) | 2003-07-02 | 2005-01-05 | Labor Becker, Olgemoeller & Kollegen GbR | Detektionsverfahren für Nucleinsäuren mit interner Amplifikationskontrolle |
KR100647277B1 (ko) | 2003-08-14 | 2006-11-17 | 삼성전자주식회사 | B형 간염 검사용 pcr 프라이머 세트 및 이를 포함하는 b형 간염 검사 키트 |
US7521184B2 (en) | 2003-08-22 | 2009-04-21 | Sirna Therapeutics, Inc. | Detection and quantitation of nucleic acid molecules in biological samples |
ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
DE10339927A1 (de) | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
US20080207539A1 (en) | 2003-09-01 | 2008-08-28 | Patrick Arbuthnot | Self-Processing Rna Expression Cassette |
JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ, インコーポレーテッド | 4’−チオヌクレオシドおよびオリゴマー化合物 |
WO2005059138A1 (en) | 2003-12-16 | 2005-06-30 | Agency For Science, Technology And Research | Methods and compounds for altering the load of hepatitis virus |
DE60330160D1 (de) | 2003-12-16 | 2009-12-31 | Bio Rad Pasteur | Oligonukleotide zur Detektion von Hepatitis B Viren |
JPWO2005116204A1 (ja) | 2004-05-11 | 2008-06-19 | 株式会社アルファジェン | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
JP2008504840A (ja) * | 2004-06-30 | 2008-02-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | 非リン酸骨格結合を含むオリゴヌクレオチド |
WO2006034545A1 (en) | 2004-09-28 | 2006-04-06 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
WO2006039739A1 (en) | 2004-10-13 | 2006-04-20 | Melbourne Health | Hepatitis b viral (hbv) mutants detection and application |
DE602005027747D1 (de) | 2004-12-22 | 2011-06-09 | Alnylam Pharmaceuticals Inc | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen |
EP1696040A1 (en) | 2005-02-28 | 2006-08-30 | Eurofins Viralliance, Inc. | Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules |
CA2600184A1 (en) | 2005-03-03 | 2006-09-08 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of adventitious viruses |
US20080096839A1 (en) | 2005-03-09 | 2008-04-24 | Mogam Biotechnology Research Institute | Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same |
US20060258610A1 (en) * | 2005-05-12 | 2006-11-16 | Isis Pharmaceuticals, Inc. | Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness |
GB0519169D0 (en) | 2005-09-21 | 2005-10-26 | Leuven K U Res & Dev | Novel anti-viral strategy |
GB0522578D0 (en) | 2005-11-04 | 2005-12-14 | King S College London | Ribozymal nucleic acid |
WO2007078029A1 (en) | 2006-01-05 | 2007-07-12 | Catch By Gene Co., Ltd. | A quantitative method for hbv-dna, a primer and probe for detecting hbv-dna, and a detecting kit comprising the same |
WO2007084567A2 (en) | 2006-01-17 | 2007-07-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus |
EP2428227B1 (en) | 2006-01-26 | 2016-06-22 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
AU2007211080B9 (en) | 2006-01-27 | 2012-05-03 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
US8178503B2 (en) | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
US8198253B2 (en) * | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
DE602006008150D1 (de) | 2006-10-12 | 2009-09-10 | Bio Rad Pasteur | Doppelsträngige Sonden zur Fluoreszenzdetektion von Nukleinsäuren |
DK2092065T4 (da) | 2006-10-18 | 2019-10-21 | Ionis Pharmaceuticals Inc | Antisense-forbindelser |
CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
CA2673622A1 (en) | 2006-12-22 | 2008-07-03 | Imuthes Limited | Lipid |
US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
US8232257B2 (en) | 2007-03-27 | 2012-07-31 | University Of Iowa Research Foundation | RNA interference mediated inactivation of hepatitis B virus in a subject |
EP2164965B1 (en) * | 2007-05-29 | 2013-09-11 | University Of The Witwatersrand, Johannesburg | A primary micro rna expression cassette |
CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
ES2376507T5 (es) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
US9434997B2 (en) | 2007-08-24 | 2016-09-06 | Lawrence Livermore National Security, Llc | Methods, compounds and systems for detecting a microorganism in a sample |
WO2009038266A1 (en) | 2007-09-17 | 2009-03-26 | Mogam Biotechnology Research Institute | Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv |
US20100255482A1 (en) | 2007-11-06 | 2010-10-07 | Siemens Healthcare Diagnostics Inc. | Hepatitis B Virus (HBV) Specific Oligonucleotide Sequences |
MX2010006039A (es) * | 2007-12-03 | 2010-06-23 | Enzon Pharmaceuticals Inc | Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica. |
EP2242846A1 (en) * | 2008-02-13 | 2010-10-27 | DSM IP Assets B.V. | Process for the production of a peptide |
CN101565756B (zh) | 2008-04-25 | 2013-07-10 | 中山大学达安基因股份有限公司 | 一种乙型肝炎病毒核苷类似物耐药相关突变检测试剂盒 |
CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
US20100015708A1 (en) | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
US8293474B2 (en) | 2008-07-02 | 2012-10-23 | National Health Research Institutes | Oligonucleotides and use thereof for determining deletion in HBV Pre-S region |
WO2010012244A1 (zh) | 2008-08-01 | 2010-02-04 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
EP3335715A3 (en) | 2008-10-15 | 2018-08-08 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
US20100211327A1 (en) | 2009-02-03 | 2010-08-19 | Prosetta Bioconformatics, Inc. | Methods and Systems for Viral Diagnosis |
US8815514B2 (en) | 2009-07-02 | 2014-08-26 | Co-Diagnostics, Inc. | Detection primers for nucleic acid extension or amplification reactions |
WO2011047312A1 (en) * | 2009-10-16 | 2011-04-21 | Glaxo Group Limited | Hbv antisense inhibitors |
US9410189B2 (en) | 2010-04-30 | 2016-08-09 | Co-Diagnostics, Inc. | Methods of preventing non-specific reactions of nucleotide sequences |
US20130137090A1 (en) | 2010-07-06 | 2013-05-30 | Aptateck Bio Ltd. | Nucleic acid aptamer-based diagnostic methods with novel techniques for signal enhancement |
EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2012045894A1 (es) | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b |
KR101903778B1 (ko) | 2010-10-28 | 2018-10-04 | 베니텍 바이오파마 리미티드 | Hbv 치료 |
EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
TW201303013A (zh) | 2011-04-21 | 2013-01-16 | Isis Pharmaceuticals Inc | B型肝炎病毒(hbv)表現之調節 |
US8809293B2 (en) | 2011-06-30 | 2014-08-19 | Arrowhead Madison Inc. | Compositions and methods for inhibiting gene expression of hepatitis B virus |
US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
-
2012
- 2012-04-20 SI SI201231882T patent/SI3505528T1/sl unknown
- 2012-04-20 CN CN202010047402.2A patent/CN111172162A/zh active Pending
- 2012-04-20 WO PCT/US2012/034550 patent/WO2012145697A1/en active Application Filing
- 2012-04-20 NZ NZ705820A patent/NZ705820A/en unknown
- 2012-04-20 LT LTEP19155538.2T patent/LT3505528T/lt unknown
- 2012-04-20 CR CR20190207A patent/CR20190207A/es unknown
- 2012-04-20 PT PT191555382T patent/PT3505528T/pt unknown
- 2012-04-20 PL PL19155538T patent/PL3505528T3/pl unknown
- 2012-04-20 MX MX2016004337A patent/MX347253B/es unknown
- 2012-04-20 AU AU2012245243A patent/AU2012245243B2/en active Active
- 2012-04-20 UA UAA201313518A patent/UA118951C2/uk unknown
- 2012-04-20 SG SG2013078043A patent/SG194555A1/en unknown
- 2012-04-20 EA EA201391572A patent/EA029137B1/ru unknown
- 2012-04-20 CN CN201280025777.2A patent/CN103582648B/zh active Active
- 2012-04-20 CN CN201610555441.7A patent/CN106191060B/zh active Active
- 2012-04-20 JP JP2014506595A patent/JP6042871B2/ja active Active
- 2012-04-20 PE PE2018000483A patent/PE20181267A1/es unknown
- 2012-04-20 TW TW101114260A patent/TWI548745B/zh active
- 2012-04-20 MY MYPI2013701973A patent/MY169474A/en unknown
- 2012-04-20 US US13/452,703 patent/US8642752B2/en active Active
- 2012-04-20 SG SG10201604074TA patent/SG10201604074TA/en unknown
- 2012-04-20 EP EP19155538.2A patent/EP3505528B1/en active Active
- 2012-04-20 ES ES19155538T patent/ES2856266T3/es active Active
- 2012-04-20 PE PE2013002380A patent/PE20141177A1/es active IP Right Grant
- 2012-04-20 HU HUE19155538A patent/HUE053401T2/hu unknown
- 2012-04-20 MX MX2013012196A patent/MX340408B/es active IP Right Grant
- 2012-04-20 EP EP12773736.9A patent/EP2699583A4/en not_active Withdrawn
- 2012-04-20 EP EP20209058.5A patent/EP3816288A3/en active Pending
- 2012-04-20 EP EP17186598.3A patent/EP3312189A1/en not_active Withdrawn
- 2012-04-20 KR KR1020197036206A patent/KR102247463B1/ko active IP Right Grant
- 2012-04-20 KR KR1020207026891A patent/KR20200110822A/ko not_active Application Discontinuation
- 2012-04-20 DK DK19155538.2T patent/DK3505528T3/da active
- 2012-04-20 NZ NZ616512A patent/NZ616512A/en unknown
- 2012-04-20 CA CA2833766A patent/CA2833766C/en active Active
- 2012-04-20 KR KR1020137030465A patent/KR102055331B1/ko active IP Right Grant
- 2012-04-20 RS RS20210190A patent/RS61447B1/sr unknown
- 2012-04-20 RU RU2013151843A patent/RU2667524C2/ru not_active Application Discontinuation
-
2013
- 2013-10-14 IL IL228874A patent/IL228874B/en active IP Right Grant
- 2013-10-14 ZA ZA2013/07620A patent/ZA201307620B/en unknown
- 2013-10-17 PH PH12013502157A patent/PH12013502157A1/en unknown
- 2013-10-21 CL CL2013003053A patent/CL2013003053A1/es unknown
- 2013-10-21 DO DO2013000246A patent/DOP2013000246A/es unknown
- 2013-10-28 CR CR20130551A patent/CR20130551A/es unknown
- 2013-11-19 CO CO13271891A patent/CO6862103A2/es active IP Right Grant
- 2013-12-20 US US14/137,111 patent/US9034841B2/en active Active
-
2014
- 2014-08-20 US US14/464,449 patent/US9127278B2/en active Active
-
2015
- 2015-07-07 US US14/793,622 patent/US9677076B2/en active Active
-
2016
- 2016-11-10 JP JP2016219348A patent/JP6426678B2/ja active Active
-
2017
- 2017-05-05 US US15/587,668 patent/US20170369883A1/en not_active Abandoned
-
2018
- 2018-10-23 JP JP2018199169A patent/JP6743106B2/ja active Active
-
2019
- 2019-07-25 IL IL268257A patent/IL268257A/en unknown
- 2019-07-25 US US16/522,490 patent/US20200190520A1/en not_active Abandoned
-
2021
- 2021-02-11 HR HRP20210244TT patent/HRP20210244T1/hr unknown
- 2021-02-16 CY CY20211100131T patent/CY1124327T1/el unknown
- 2021-07-30 US US17/389,599 patent/US20220064650A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210244T1 (hr) | Moduliranje eksprimiranja virusa hepatitisa b (hbv) | |
HRP20190987T1 (hr) | Kompozicije i postupci za modulaciju ekspresije hbv i ttr | |
JP2014513954A5 (hr) | ||
HRP20211051T1 (hr) | Pripravci namijenjeni moduliranju eksprimiranja tau | |
HRP20201426T1 (hr) | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) | |
JP2012105686A5 (hr) | ||
HRP20211397T1 (hr) | Pripravci za modulaciju ekspresije ataksina 2 | |
FI2906696T4 (fi) | Menetelmiä c9orf72:n ilmentymisen moduloimiseksi | |
HRP20191883T1 (hr) | Modulacija ekspresije tmprss6 | |
JP2016116520A5 (hr) | ||
JP2014530004A5 (hr) | ||
HRP20211410T1 (hr) | Pripravci i postupci za inhibiciju ekspresije gena lpa | |
HRP20190303T1 (hr) | Liječenje raka | |
NO2019001I1 (no) | Forbindelse omfattende et modifisert oligonukleotid som har en nukleobasesekvens bestående av 20 koblede nukleosider ifølge EP B1 2563920 krav 1 (SEQ ID NO: 80), hvor det modifiserte oligonukleotidet omfatter: et avstandssegment bestående av ti koblede deoksynukleosider; et 5'-vingesegment bestående av fem koblede nukleosider; og et 3'-vingesegment bestående av fem koblede nukleosider; hvor avstandssegmentet er plassert mellom 5'-vingesegmentet og 3'-vingesegmentet, hvor hvert nukleosid av hvert vingesegment omfatter et 2'-0-metoksyetylsukker; hvor hver cytosin av det modifiserte oligonukleotid er en 5-metylcytosin, og hvor hver internukleosid-binding av det modifiserte oligonukleotid er en fosfortioatbinding; og spesielt inotersen; og dets derivater, så som dets salter, inkludert natriumsalter. | |
JP2013516489A5 (hr) | ||
RU2016116849A (ru) | Композиции для модуляции экспрессии c90rf72 | |
JP2015142558A5 (hr) | ||
JP2013226147A5 (hr) | ||
JP2015529635A5 (hr) | ||
JP2020500929A5 (hr) | ||
JP2015536132A5 (hr) | ||
JP2017510271A5 (hr) | ||
RU2016129725A (ru) | Модуляция экспрессии ангиопоэтин-подобного белка 3 | |
RU2015133252A (ru) | Лечение возрастной макулярной дегенерации | |
JP2017536119A5 (hr) |